 |
|
|
| |
LONG-TERM PATIENT ADHERENCE AND MANAGEMENT OF TREATMENT INTERRUPTIONS WITH LONG-ACTING INJECTABLE CABOTEGRAVIR + RILPIVIRINE FOR MAINTENANCE THERAPY IN PHASE 2B/3 STUDIES
|
| |
| |
IDWeek 2020 Oct 21-25
Reported by Jules levin
Paula Teichner1, Sterling Wu2, Feifan Zhang2, David Dorey3, Ronald D'Amico1, Sandy Griffith1, Kenneth Sutton1, Cynthia McCoig4, Ojesh Upadhyay2,
Joseph W. Polli1, David A. Margolis1, Rodica Van Solingen-Ristea5, Kati Vandermeulen5, William R. Spreen1, Parul Patel1
1ViiV Healthcare, Research Triangle Park, NC, United States; 2GlaxoSmithKline, Upper Providence, PA, United States; 3GlaxoSmithKline, Mississauga, Canada; 4ViiV Healthcare,
Tres Cantos, Spain; 5Janssen Research and Development, Beerse, Belgium
|
| |
|
|
|
|
|
